Home › Funds › PRENTISS SMITH & CO INC › REGN
PRENTISS SMITH & CO INC position in REGN
REGENERON PHARMACEUTICALS · Health Care
PRENTISS SMITH & CO INC reported holding 2,022 shares of REGN (REGENERON PHARMACEUTICALS) in its Q3 2026 13F filing — a position valued at US$1.5M, representing 0.87% of its reported portfolio and ranking #31 among its reported holdings. PRENTISS SMITH & CO INC has disclosed REGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How PRENTISS SMITH & CO INC's REGN position evolved
PRENTISS SMITH & CO INC first disclosed a stake in REGN in Q3 2023 at 5,435 shares (US$4.5M). Across 13 filings, PRENTISS SMITH & CO INC increased the stake 1 time(s), trimmed it 9 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 2,022 shares valued at US$1.5M — a reduction of -16 shares quarter over quarter.. Notable position changes include a 33% trim in Q4 2023 (shares rose 10% over the following quarter), a 41% trim in Q2 2024 (shares were roughly flat over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 5.43K | $4.47M | New |
| Q4 2023 | 3.66K | $3.21M | Reduce |
| Q1 2024 | 3.54K | $3.41M | Reduce |
| Q2 2024 | 2.09K | $2.20M | Reduce |
| Q3 2024 | 2.04K | $2.14M | Reduce |
| Q4 2024 | 2.04K | $1.45M | Hold |
| Q1 2025 | 2.11K | $1.34M | Add |
| Q2 2025 | 2.09K | $1.10M | Reduce |
| Q3 2025 | 2.08K | $1.17M | Reduce |
| Q4 2025 | 2.06K | $1.59M | Reduce |
| Q1 2026 | 2.06K | $1.59M | Hold |
| Q2 2026 | 2.04K | $1.27M | Reduce |
| Q3 2026 | 2.02K | $1.53M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About REGN and 13F data
REGN (REGENERON PHARMACEUTICALS) is a Health Care company. 29 other funds we track also report a position in REGN — the largest reported positions include Dodge & Cox (US$3.04B), DODGE & COX (US$3.04B), Franklin Resources (US$2.75B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding REGN
- Dodge & Cox 4.87M sh · $3.04B · Q2 2026
- DODGE & COX 4.87M sh · $3.04B · Q2 2026
- Franklin Resources 2.95M sh · $2.75B · Q3 2026
- Nuveen, LLC 1.96M sh · $1.48B · Q3 2026
- LOOMIS SAYLES & CO L P 1.72M sh · $1.30B · Q3 2026
More on PRENTISS SMITH & CO INC
FAQ
How long has PRENTISS SMITH & CO INC held REGN?
PRENTISS SMITH & CO INC has disclosed REGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is PRENTISS SMITH & CO INC's current position in REGN?
As of Q3 2026, PRENTISS SMITH & CO INC holds 2.02K shares of REGN (REGENERON PHARMACEUTICALS), valued at $1.53M, representing 0.87% of its reported portfolio and ranking #31.
Has PRENTISS SMITH & CO INC been buying or selling REGN?
In the latest 13F filing (Q3 2026), PRENTISS SMITH & CO INC reduced its position in REGN.
Which other funds hold REGN?
Other major institutional holders of REGN include Dodge & Cox, DODGE & COX, Franklin Resources, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.